SANJEEV KAMAT: Open Payments
NPI 1649375288 · SAINT LOUIS, MO. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,348 in 97 payments from 13 companies in 2025. Trend: 2023 $1,739 · 2024 $2,472 · 2025 $2,348
Food & beverage: $2,341Education: $8
| Company | Payments | Amount |
|---|---|---|
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 19 | $547 |
| Alkermes, Inc. | 14 | $460 |
| Vanda Pharmaceuticals Inc. | 13 | $305 |
| E.R. Squibb & Sons, L.L.C. | 23 | $275 |
| ABBVIE INC. | 6 | $167 |
| Janssen Pharmaceuticals, Inc | 7 | $150 |
| Otsuka America Pharmaceutical, Inc. | 1 | $122 |
| Lundbeck LLC | 3 | $69 |
| Lilly USA, LLC | 3 | $62 |
| Teva Pharmaceuticals USA, Inc. | 3 | $57 |
Products named: CAPLYTA, ARISTADA, FANAPT, COBENFY, REXULTI, VRAYLAR, LYBALVI, INVEGA SUSTENNA.
Industry payments across MO — which companies pay providers there.
